Tags

Type your tag names separated by a space and hit enter

Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Eur J Obstet Gynecol Reprod Biol. 2006 May 01; 126(1):93-8.EJ

Abstract

OBJECTIVE

The aim of our study is to investigate and compare the clinical, biochemical and hormonal changes during application of insulin-sensitizers from two different groups.

STUDY DESIGN

This prospective, open clinical study lasted 3 months and included 30 women with PCOS, divided in two groups of 15 women each. Group 1 received 850 mg metformin twice a day and group 2 was treated with rosiglitazone 4 mg a day. Serum levels of testosterone, immune reactive insulin (IRI), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS) and lipid metabolism parameters were measured before the treatment, and on the 3rd month. Free androgen index (FAI) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. Body mass index (BMI) and waist-to-hip ratio (WHR) were assessed at baseline and at the end of therapy.

RESULTS

Two parameters change significantly in the 3rd month in our study--testosterone and insulin. Much better decrease in the level of testosterone and free androgen index was established in group treated with metformin, while the indices of insulin resistance were better influenced in the group treated with rosiglitazone.

CONCLUSION

Application of insulin sensitizers from both groups has a favorable influence on the basic hormonal deviations in PCOS--the hyperandrogenemia and the insulin resistance. In cases with PCOS metformin treatment influences better hyperandrogenemia, while rosiglitazone affects more pronouncedly insulin resistance and hyperinsulinemia.

Authors+Show Affiliations

Department of Endocrinology, Medical University, Plovdiv, Bulgaria.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

16360262

Citation

Mitkov, M, et al. "Metformin Versus Rosiglitazone in the Treatment of Polycystic Ovary Syndrome." European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 126, no. 1, 2006, pp. 93-8.
Mitkov M, Pehlivanov B, Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2006;126(1):93-8.
Mitkov, M., Pehlivanov, B., & Terzieva, D. (2006). Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 126(1), 93-8.
Mitkov M, Pehlivanov B, Terzieva D. Metformin Versus Rosiglitazone in the Treatment of Polycystic Ovary Syndrome. Eur J Obstet Gynecol Reprod Biol. 2006 May 1;126(1):93-8. PubMed PMID: 16360262.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. AU - Mitkov,M, AU - Pehlivanov,B, AU - Terzieva,D, Y1 - 2005/12/19/ PY - 2005/05/01/received PY - 2005/11/14/revised PY - 2005/11/15/accepted PY - 2005/12/20/pubmed PY - 2006/12/9/medline PY - 2005/12/20/entrez SP - 93 EP - 8 JF - European journal of obstetrics, gynecology, and reproductive biology JO - Eur J Obstet Gynecol Reprod Biol VL - 126 IS - 1 N2 - OBJECTIVE: The aim of our study is to investigate and compare the clinical, biochemical and hormonal changes during application of insulin-sensitizers from two different groups. STUDY DESIGN: This prospective, open clinical study lasted 3 months and included 30 women with PCOS, divided in two groups of 15 women each. Group 1 received 850 mg metformin twice a day and group 2 was treated with rosiglitazone 4 mg a day. Serum levels of testosterone, immune reactive insulin (IRI), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS) and lipid metabolism parameters were measured before the treatment, and on the 3rd month. Free androgen index (FAI) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. Body mass index (BMI) and waist-to-hip ratio (WHR) were assessed at baseline and at the end of therapy. RESULTS: Two parameters change significantly in the 3rd month in our study--testosterone and insulin. Much better decrease in the level of testosterone and free androgen index was established in group treated with metformin, while the indices of insulin resistance were better influenced in the group treated with rosiglitazone. CONCLUSION: Application of insulin sensitizers from both groups has a favorable influence on the basic hormonal deviations in PCOS--the hyperandrogenemia and the insulin resistance. In cases with PCOS metformin treatment influences better hyperandrogenemia, while rosiglitazone affects more pronouncedly insulin resistance and hyperinsulinemia. SN - 0301-2115 UR - https://www.unboundmedicine.com/medline/citation/16360262/Metformin_versus_rosiglitazone_in_the_treatment_of_polycystic_ovary_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0301-2115(05)00647-0 DB - PRIME DP - Unbound Medicine ER -